MedPath

The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV

Phase 4
Completed
Conditions
Palonosetron
Anesthesia
PONV
Interventions
Registration Number
NCT02809378
Lead Sponsor
Ajou University School of Medicine
Brief Summary

The incidence of postoperative nausea and vomiting (PONV) after thyroidectomy have been shown to be relatively high compared other surgeries, with a reported incidence 65-75 %. PONV may increase patient discomfort, delay patient discharge, and increase the cost of patient care, the risk of postoperative bleeding which may potentially cause airway obstruction.

It is reported that the maintenance of anesthesia with propofol-remifentanil or sevoflurane-propofol-remifentanil decreased the incidence of PONV compared sevoflurane alone, but failed to demonstrate the decreased incidence of PONV in 6-24 hr postoperative period in patients undergoing thyroidectomy. Administration of Palonosetron, newly developed 5-HT3 antagonists with long half life (48 hrs) may decrease the incidence of PONV particularly during this period.

The purpose of this study was to evaluate and compare the incidence of PONV after thyroidectomy with three different anesthetic methods, sevoflurane or sevoflurane-propofol-remifentanil or sevoflurane-propofol-remifentanil-palonosetron in woman patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • patients undergoing thyroidectomy euthyroid status American Society of Anesthesiology Physical status 1,2
Exclusion Criteria
  • Ideal body weight >130% gastrointestinal disease prior administration of anti-emetics (24hr)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sevofluranepentothal sodiumanesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
sevoflurane, remifentanil, and propofolremifentanilanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
Sevoflurane, remifentanil, propofol, and palonosetronsevofluraneanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
sevoflurane, remifentanil, and propofolsevofluraneanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
Sevofluranesevofluraneanesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
sevoflurane, remifentanil, and propofolpropofolanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
Sevoflurane, remifentanil, propofol, and palonosetronPalonosetronanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
Sevoflurane, remifentanil, propofol, and palonosetronremifentanilanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
Sevoflurane, remifentanil, propofol, and palonosetronpropofolanesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
Primary Outcome Measures
NameTimeMethod
incidence of postoperative nausea and vomiting24 hour postoperative
Secondary Outcome Measures
NameTimeMethod
incidence of postoperative nausea and vomiting48 hour postoperative

Trial Locations

Locations (1)

Ajou universiry hospital

🇰🇷

Suwon, Gyeonggi-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath